Mergers and Acquisitions
-
Will it? Won’t It? CVS Health To Finally Acquire Oak Street Health for $10.6B
Rumors of the deal first surfaced in January, with some dismissing the idea. Several experts say the deal makes sense for CVS Health, as it looks to expand into primary and value-based senior care.
-
Sun Pharma Strikes $576M Deal to Get Hair Loss Drug to Rival Lilly, Pfizer Meds
Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Consumer / Employer, Health Tech
CVS Health Makes Waves During JPM: Experts Weigh In
CVS Health announced investments this week in Carbon Health, Monogram Health and Array Behavioral Care. There have also been rumors that the company is exploring a $10 billion deal with primary care company Oak Street Health.
-
LeanTaaS Acquires Hospital IQ to Create $1B Healthcare Automation Company
LeanTaaS acquired healthcare automation company Hospital IQ. The two companies made the deal because their products complement each other — Hospital IQ provides staff optimization solutions, while LeanTaaS makes software to optimize capacity for operating rooms, infusion centers and inpatient beds.
-
All About Access: The Key Trends In Retailers’ Acquisitions in 2022
Whether it was Amazon’s buy of One Medical or CVS Health’s acquisition of Signify Health, retailers made waves in healthcare this year. Across all of the deals, it’s clear that expanding access to medical services is the key goal, experts said. And this is only the beginning.
-
Does the Rumored Amwell/Talkspace Deal Make Sense? Experts Weigh In
Some industry experts seem skeptical of the rumored deal between Amwell and Talkspace, while others disagree. The rumored purchasing price is $200 million at about $1.50 per share.
-
Merck’s $1.3B Imago Buyout Brings Blood Cancer Drug to Rival BMS, Incyte & GSK
Merck is acquiring Imago BioSciences, a clinical-stage biotech whose lead drug is in development for myelofibrosis and other blood cancers. The deal gives the pharmaceutical giant a small molecule that could provide an alternative to a class of drugs that introduce dangerous side effects.
-
Viatris Sees Vision Drugs as Key to Growth and Commits $750M to Two M&A Deals
Two years after the close of the merger that formed Viatris, the company is acquiring Oyster Point Pharma and Famy Life Sciences to expand its scope in ophthalmology, one of three therapeutic areas it is now focusing on for revenue growth.
-
Hint Health To Offer Expanded Direct Primary Care Platform Through New Acquisition
Hint Health acquired AeroDPC, a software company and electronic medical record for direct primary care clinics. As a result, Hint will release a new product in 2023 that combines tools from both companies.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Genfit spreads its bets in a rare liver disease with buyout of Phase 2-ready biotech
Liver disease remains the focus of Genfit, despite a high-profile clinical trial failure in the fatty liver disease NASH. The company is building out its pipeline by acquiring Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a deadly chronic liver disease complication that has no FDA-approved therapies.
-
As M&A costs rise, new Accenture report offers alternative strategies
Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. The firm expects growth-minded companies will turn to other pathways.
-
GSK gets pneumococcal vaccine contender with $2.1B Affinivax acquisition
Pfizer and Merck have each won FDA approvals in the past year for new pneumococcal vaccines, but GSK aims to top both of them with its $2.1 billion acquisition of Affinivax. That biotech’s Phase 3-ready vaccine candidate addresses more bacterial strains than any pneumococcal vaccines currently available.
-
Collegium diversifies with $604M BDSI buyout, adding pain & migraine meds
Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.
-
UCB is expanding its reach in epilepsy with $1.9B Zogenix acquisition
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker’s ability to address that market. Zogenix’s Fintepla is approved in the U.S. and Europe for a rare type of epilepsy called Dravet syndrome, and is in development for other rare epilepsies.
-
Novartis commits $1.5B to acquire eye disease gene therapy biotech Gyroscope
Novartis is acquiring gene therapy developer Gyroscope Therapeutics and its lead program, a potential treatment for the vision loss disorder geographic atrophy. It’s the latest in a series of M&A moves made by Novartis to build up its gene therapy pipeline.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
